dc.contributor.author |
Dirix, LY |
|
dc.contributor.author |
Takács, István |
|
dc.contributor.author |
Jerusalem, G |
|
dc.contributor.author |
Nikolinakos, P |
|
dc.contributor.author |
Arkenau, HT |
|
dc.contributor.author |
Forero-Torres, A |
|
dc.contributor.author |
Boccia, R |
|
dc.contributor.author |
Lippman, ME |
|
dc.contributor.author |
Somer, R |
|
dc.contributor.author |
Smakal, M |
|
dc.contributor.author |
Emens, LA |
|
dc.contributor.author |
Hrinczenko, B |
|
dc.contributor.author |
Edenfield, W |
|
dc.contributor.author |
Gurtler, J |
|
dc.contributor.author |
von Heydebreck, A |
|
dc.contributor.author |
Grote, HJ |
|
dc.contributor.author |
Chin, K |
|
dc.contributor.author |
Hamilton, EP |
|
dc.date.accessioned |
2020-10-08T07:10:27Z |
|
dc.date.available |
2020-10-08T07:10:27Z |
|
dc.date.issued |
2018 |
|
dc.identifier |
85031927832 |
|
dc.identifier.citation |
journalVolume=167;journalIssueNumber=3;journalTitle=BREAST CANCER RESEARCH AND TREATMENT;pagerange=671-686;journalAbbreviatedTitle=BREAST CANCER RES TR; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/7198 |
|
dc.identifier.uri |
doi:10.1007/s10549-017-4537-5 |
|
dc.description.abstract |
PURPOSE: Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. METHODS: In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after standard-of-care therapy received avelumab intravenously 10 mg/kg every 2 weeks. Tumors were assessed every 6 weeks by RECIST v1.1. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Membrane PD-L1 expression was assessed by immunohistochemistry (Dako PD-L1 IHC 73-10 pharmDx). RESULTS: A total of 168 patients with MBC, including 58 patients with triple-negative breast cancer (TNBC), were treated with avelumab for 2-50 weeks and followed for 6-15 months. Patients were heavily pretreated with a median of three prior therapies for metastatic or locally advanced disease. Grade >/= 3 treatment-related AEs occurred in 13.7% of patients, including two treatment-related deaths. The confirmed objective response rate (ORR) was 3.0% overall (one complete response and four partial responses) and 5.2% in patients with TNBC. A trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1- tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%). CONCLUSION: Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC. |
|
dc.format.extent |
671-686 |
|
dc.relation.ispartof |
urn:issn:0167-6806 |
|
dc.title |
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study |
|
dc.type |
Journal Article |
|
dc.date.updated |
2019-07-08T13:12:36Z |
|
dc.language.rfc3066 |
en |
|
dc.rights.holder |
NULL |
|
dc.identifier.mtmt |
3355064 |
|
dc.identifier.wos |
000424656700006 |
|
dc.identifier.pubmed |
29063313 |
|
dc.contributor.department |
SE/AOK/K/I. Sz. Belgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|